Assessing Agilent Technologies (A) Valuation After Recent Share Price Weakness

FierceBiotechEli Lilly’s M&A spree continues with acquisition of non-opioid pain drugmaker 4E

FierceBiotechAmenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling

Endpoints NewsFDA greenlights Colorado's drug import proposal

CellThe critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM

FierceBiotechPE firm Altaris scoops up AI drug development outfit Simulations Plus for $375M

BioPharma DiveLilly buys non-opioid pain drugmaker 4E

BioPharma DiveExpress Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies

BioWorldChinese challenger Gan & Lee gains momentum in metabolic disease

BioWorldElixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorldChina partnerships drive biopharma’s biggest deal month since 2023

BioWorldOricell brings first pivotal-stage CAR T in liver cancer

BioWorldLaekna licenses LAE-118 ex-China to Vasque in $527M deal